These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 16126936)

  • 41. Identifying the lowest effective dose of acetazolamide for the prophylaxis of acute mountain sickness: systematic review and meta-analysis.
    Low EV; Avery AJ; Gupta V; Schedlbauer A; Grocott MP
    BMJ; 2012 Oct; 345():e6779. PubMed ID: 23081689
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effect of acetazolamide on saccadic latency at 3459 meters.
    Faull OK; Robertson J; Thomas O; Bradwell AR; Antoniades CA; Pattinson KT;
    Wilderness Environ Med; 2015 Mar; 26(1):72-7. PubMed ID: 25712298
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Acute mountain sickness: controversies and advances.
    Bartsch P; Bailey DM; Berger MM; Knauth M; Baumgartner RW
    High Alt Med Biol; 2004; 5(2):110-24. PubMed ID: 15265333
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Acetazolamide for the prevention of acute mountain sickness--a systematic review and meta-analysis.
    Ritchie ND; Baggott AV; Andrew Todd WT
    J Travel Med; 2012; 19(5):298-307. PubMed ID: 22943270
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Decreased plasma soluble erythropoietin receptor in high-altitude excessive erythrocytosis and Chronic Mountain Sickness.
    Villafuerte FC; Macarlupú JL; Anza-Ramírez C; Corrales-Melgar D; Vizcardo-Galindo G; Corante N; León-Velarde F
    J Appl Physiol (1985); 2014 Dec; 117(11):1356-62. PubMed ID: 25324511
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Altitude Sickness Prevention with Ibuprofen Relative to Acetazolamide.
    Burns P; Lipman GS; Warner K; Jurkiewicz C; Phillips C; Sanders L; Soto M; Hackett P
    Am J Med; 2019 Feb; 132(2):247-251. PubMed ID: 30419226
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The effect of acetazolamide on sleep apnea at high altitude: a systematic review and meta-analysis.
    Liu HM; Chiang IJ; Kuo KN; Liou CM; Chen C
    Ther Adv Respir Dis; 2017 Jan; 11(1):20-29. PubMed ID: 28043212
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of acetazolamide and CPAP on cortical activity in obstructive sleep apnea patients.
    Stadelmann K; Latshang TD; Nussbaumer-Ochsner Y; Tarokh L; Ulrich S; Kohler M; Bloch KE; Achermann P
    PLoS One; 2014; 9(4):e93931. PubMed ID: 24710341
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Acetazolamide for the treatment of acute mountain sickness.
    Tapia L; Irarrázaval S
    Medwave; 2019 Dec; 19(11):e7737. PubMed ID: 31891352
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Carbonic anhydrase inhibitors and high altitude illnesses.
    Swenson ER
    Subcell Biochem; 2014; 75():361-86. PubMed ID: 24146388
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of acetazolamide on overnight oxygenation and acute mountain sickness in patients with asthma.
    Mirrakhlmov M; Brimkulov N; Cieslicki J; Tobiasz M; Kudaiberdiev Z; Moldotashev I; Shmidt G; Zielinski J
    Eur Respir J; 1993 Apr; 6(4):536-40. PubMed ID: 8491304
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inhaled budesonide and oral dexamethasone prevent acute mountain sickness.
    Zheng CR; Chen GZ; Yu J; Qin J; Song P; Bian SZ; Xu BD; Tang XG; Huang YT; Liang X; Yang J; Huang L
    Am J Med; 2014 Oct; 127(10):1001-1009.e2. PubMed ID: 24784698
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Altitude illness: risk factors, prevention, presentation, and treatment.
    Fiore DC; Hall S; Shoja P
    Am Fam Physician; 2010 Nov; 82(9):1103-10. PubMed ID: 21121556
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pathophysiology and epidemiology of chronic mountain sickness.
    Monge-C C; Arregui A; León-Velarde F
    Int J Sports Med; 1992 Oct; 13 Suppl 1():S79-81. PubMed ID: 1483802
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Peripheral arterial desaturation is further exacerbated by exercise in adolescents with acute mountain sickness.
    Major SA; Hogan RJ; Yeates E; Imray CH
    Wilderness Environ Med; 2012 Mar; 23(1):15-23. PubMed ID: 22441084
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Reduced Acetazolamide Dosing in Countering Altitude Illness: A Comparison of 62.5 vs 125 mg (the RADICAL Trial).
    McIntosh SE; Hemphill M; McDevitt MC; Gurung TY; Ghale M; Knott JR; Thapa GB; Basnyat B; Dow J; Weber DC; K Grissom C
    Wilderness Environ Med; 2019 Mar; 30(1):12-21. PubMed ID: 30630671
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Spironolactone does not prevent acute mountain sickness: a prospective, double-blind, randomized, placebo-controlled trial by SPACE Trial Group (spironolactone and acetazolamide trial in the prevention of acute mountain sickness group).
    Basnyat B; Holck PS; Pun M; Halverson S; Szawarski P; Gertsch J; Steif M; Powell S; Khanal S; Joshi A; Shankar R; Karambay J; Alexander HD; Stone A; Morrissey C; Thompson BH; Farrar J;
    Wilderness Environ Med; 2011 Mar; 22(1):15-22. PubMed ID: 21377114
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Acetazolamide treatment for infantile central sleep apnea.
    Philippi H; Bieber I; Reitter B
    J Child Neurol; 2001 Aug; 16(8):600-3. PubMed ID: 11510934
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prophylaxis for acute mountain sickness.
    Fisher JA
    Hosp Pract (1995); 1998 Mar; 33(3):23. PubMed ID: 9522828
    [No Abstract]   [Full Text] [Related]  

  • 60. How to treat patients with obstructive sleep apnea syndrome during an altitude sojourn.
    Latshang TD; Bloch KE
    High Alt Med Biol; 2011; 12(4):303-7. PubMed ID: 22206552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.